Session (CTI)

"Issue"Central & Eastern European (CEE) payers face a paradox: single-payer systems give them rich RWD streams yet reimbursement dossiers still require long timelines for both creation and adjudication, driven by capacity limitations. "Overview"Overview provided by three expert speakers with a combined presentation time of approximately 36 minutes, followed by a 20-minute moderated discussion. The session will begin with a representative of the Polish HTA agency, who will provide an overview of the CEE HTA landscape, using Poland as a case study. This presentation will examine payer structures, highlight resource limitations, and outline major barriers to implementing AI in HTA, including data standardization challenges, regulatory uncertainty, methodological concerns such as algorithm validation and transparency, and ethical issues related to patient privacy, algorithmic bias, and informed consent.The second speaker, an HTA methodologist, will explore how AI is currently applied in literature reviews. This presentation will cover the benefits of AI integration, such as increased efficiency and quality control, while also addressing potential pitfalls including reproducibility issues, unclear regulatory frameworks, and the risk of data manipulation or falsification.The third speaker, an expert in AI and data science, will present a technical deep-dive into how AI tools can support accelerated evidence synthesis and dossier preparation, enable analysis of linked real-world data and synthesis of patient-reported outcomes, cost-effectiveness data, and enhance interpretation of complex data through traceable and transparent processes.The session will conclude with a 20-minute moderated discussion, including two live polls to assess audience perspectives on AI readiness in HTA and acceptable standards of evidence. The moderator will guide a dialogue focused on setting minimum validation criteria and exploring the potential for cross-border data-sharing.This session will be of particular value to national payers, HTA bodies, policymakers, pharmaceutical market access and HEOR teams, as well as AI technology vendors.